The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2 / Phase 3	2025-03-20		NCT04513639

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Alesund Hospital	40
Førde Central Hospital	1
Haukeland University Hospital	163
Helse Nord-Trøndelag HF	21
Helse Stavanger HF	67
Nordlandssykehuset HF	22
Oslo University Hospital	327
Sorlandet Hospital HF	42
St. Olavs Hospital	167
Sykehuset Ostfold	8
The Hospital of Vestfold	15
University Hospital of North Norway	93
University Hospital, Akershus	87

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Akershus University Hospital	Lørenskog	Norway	16
Førde Central Hospital	Førde	Norway	2
Haukeland University Hospital	Bergen	Norway	52
Helse Stavanger HF	Stavanger	Norway	1
Levanger hospital	Levanger	Norway	2
Nordland Hospital Bodø	Bodø	Norway	2
Oslo University Hospital	Oslo	Norway	111
St. Olavs hospital	Trondheim	Norway	17
Sykehuset Ostfold	Fredrikstad	Norway	1
Sørlandet Hospital Kristiansand	Kristiansand	Norway	2
The Hospital of Vestfold	Tønsberg	Norway	1
University hospital North Norway	Tromsø	Norway	3
Ålesund Hospital	Ålesund	Norway	10